These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35208221)

  • 21. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.
    Noda K; Kato T; Nomura N; Sakai M; Kubota S; Hirose T; Liu Y; Takahashi Y; Takao K; Mizuno M; Hirota T; Suwa T; Horikawa Y; Yabe D
    Diabetol Int; 2022 Oct; 13(4):693-697. PubMed ID: 36117924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GREATER COMBINED REDUCTIONS IN HbA
    Rodbard HW; Bellary S; Hramiak I; Seino Y; Silver R; Damgaard LH; Nayak G; Zacho J; Aroda VR
    Endocr Pract; 2019 Jun; 25(6):589-597. PubMed ID: 30865526
    [No Abstract]   [Full Text] [Related]  

  • 23. Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings.
    Yamada H; Yoshida M; Funazaki S; Morimoto J; Tonezawa S; Takahashi A; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    J Cardiovasc Dev Dis; 2023 Apr; 10(4):. PubMed ID: 37103055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma.
    Gjersdal E; Larsen LB; Ettrup KS; Vestergaard P; Nielsen EH; Karmisholt JS; Müller HL; Dal J
    Pituitary; 2024 Aug; ():. PubMed ID: 39088138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
    Brunton SA; Mosenzon O; Wright EE
    Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.
    Inoue K; Maeda N; Kashine S; Fujishima Y; Kozawa J; Hiuge-Shimizu A; Okita K; Imagawa A; Funahashi T; Shimomura I
    Cardiovasc Diabetol; 2011 Dec; 10():109. PubMed ID: 22132774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.
    Yamada H; Yoshida M; Suzuki D; Funazaki S; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    Diabetes Ther; 2022 Oct; 13(10):1779-1788. PubMed ID: 36006593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.
    Wharton S; Batterham RL; Bhatta M; Buscemi S; Christensen LN; Frias JP; Jódar E; Kandler K; Rigas G; Wadden TA; Garvey WT
    Obesity (Silver Spring); 2023 Mar; 31(3):703-715. PubMed ID: 36655300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
    Webb N; Orme M; Witkowski M; Nakanishi R; Langer J
    Diabetes Ther; 2018 Jun; 9(3):973-986. PubMed ID: 29574633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
    Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
    Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Semaglutide in the Management of Type 2 DM: Clinical Status and Comparative Analysis.
    Bandyopadhyay I; Dave S; Rai A; Nampoothiri M; Chamallamudi MR; Kumar N
    Curr Drug Targets; 2022; 23(3):311-327. PubMed ID: 34468297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
    Friedrichsen M; Breitschaft A; Tadayon S; Wizert A; Skovgaard D
    Diabetes Obes Metab; 2021 Mar; 23(3):754-762. PubMed ID: 33269530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
    Jensen AB; Renström F; Aczél S; Folie P; Biraima-Steinemann M; Beuschlein F; Bilz S
    Obes Surg; 2023 Apr; 33(4):1017-1025. PubMed ID: 36765019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists.
    Okamoto A; Yokokawa H; Nagamine T; Fukuda H; Hisaoka T; Naito T
    J Diabetes Metab Disord; 2021 Dec; 20(2):2121-2128. PubMed ID: 34900848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity.
    Nicolau J; Pujol A; Tofé S; Bonet A; Gil A
    Physiol Behav; 2022 Dec; 257():113967. PubMed ID: 36162525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.